The most promising vaccine against the coronavirus to date is also an example of the long-term value of curiosity-driven basic research and its funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation).
The so-called mRNA vaccine platform, which the Mainz-based company BioNTech uses in its Covid-19 vaccine developed jointly with the US pharmaceutical company Pfizer, can be traced back to preliminary work carried out from 2006 to 2008 in a project within a DFG-funded Collaborative Research Centre (CRC) on cancer research at the Johannes Gutenberg University Mainz. This in turn was also tied to previous DFG-funded research.
The project was led by the later founder and current CEO of BioNTech, Professor Dr. Uur ahin, whose name and person are closely associated with the development of the BNT162b2 vaccine, which will be deployed immediately following its approval in the United Kingdom and its anticipated approval in the USA and the EU.
In addition to him, Privatdozent Dr. zlem Treci, ahin's wife, who as Chief Medical Officer of BioNTech is also significantly involved in the Covid-19 vaccine, conducted research in a project in the Collaborative Research Centre.
The spokesperson of the CRC was immunologist and oncologist Professor Dr. Christoph Huber, who was also one of the subsequent founders of BioNTech and is now a member of the company's supervisory board.
ahin describes the work funded by the DFG as "important contributions" towards exploring fundamental scientific issues on the path to the currently deployed mRNA vaccine platform. "That preliminary work helped lay the foundations for the development of our vaccine," states ahin.
The CRC in which ahin conducted his work received funding of approximately 19 million from 1997 to 2008. He conducted research on "mechanisms of tumor defense and their therapeutic implications" in two major areas with more than a dozen projects each. ahin was initially involved in the CRC as of 2000 as the head of an independent junior research group.
He received further funding in a Research Training Group from 2004, just like zlem Treci, who was granted a habilitation fellowship and funded under the DFG's Heisenberg Programme.
ahin's project was set up in 2006 in the final funding period for the CRC and initially led by him as a Privatdozent before he was appointed to a professorship in experimental oncology. The project received over 300,000 in funds before the CRC ended in 2008.
Under the title "Development of mRNA-based vaccines to induce integrated T- and B-cell immune responses against molecularly defined tumor antigens," the project aimed to control and destroy tumors by directly activating the body's own immune system, which is a fundamentally different approach to therapy than radiation or chemotherapy.
This approach involves the tumor antigens on the surface of tumor cells being identified and their genetic information deciphered. The genetic blueprint obtained in this way can then be used as a template or platform for the development and technological production of a vaccine specifically directed to target tumor antigens.
Ribonucleic acids (mRNA) are used as a vaccine substance. They inform the immune system about the tumor antigens to be combated and then rapidly degrade, thus leaving no permanent genetic changes in the genome.
This approach of so-called mRNA vaccination is in turn based on other preliminary work from the 1990s. This included work in a Collaborative Research Centre at the University of Tbingen funded by the DFG from 1997 to 2004.
Co-workers in the CRC led by immunologist Professor Dr. Hans-Georg Rammensee on the main topic entitled "Stem cells and antigen recognition in the hematopoietic system. From hematopoietic stem cells to immunotherapy" included, among others, Dr. Ingmar Hoerr, who obtained his doctorate there within a project and then went on to found the biotech company Curevac, which is also currently working to develop a coronavirus vaccine.
ahin himself continued the work started in the CRC within the framework of several grants from the German Federal Ministry of Education and Research (BMBF) and in the DFG-funded Research Centre Translational Oncology (TRON), which he co-founded in 2010, at Mainz University Medical Centre, and, since 2008, in his spin-off BioNTech, where this work has now contributed to the development of the coronavirus vaccine.
The immune system has evolved over millions of years to provide us with optimum protection against pathogens, such as viruses. Our early research addressed the question of how we can further improve these immune mechanisms and use them to fight cancer cells. Now we've been able to build on this knowledge. Using a vaccine to activate the immune system against SARS-CoV-2 is in comparison an easier challenge than overcoming self-tolerance against cancer."
Dr. Uur ahin, Professor and Later Founder, Current CEO of BioNTech
"The years we spent crossing the borders between basic research and application also served us well. It is never a one-way process, but rather the findings from basic research constantly stimulate translation - just as application-oriented research provides findings and raises new questions, which then have to be studied again from a basic research perspective," concludes ahin.
In addition to his activity at BioNTech, the researcher continues to be a Professor of Experimental Oncology at the University of Mainz and continues to receive DFG funding as a project head in three CRCs that are currently ongoing.
DFG President Professor Dr. Katja Becker congratulated ahin and his staff on the development of their vaccine, stating: "The DFG is very pleased to have had the opportunity of making its contribution to the early findings. These are now being used in the successful university spin-off which developed the vaccine that promises so much hope. Its development reveals the essential nature of research that derives knowledge solely based on scientific curiosity, and whose true value often lies in the very fact that it is unpredictable. No one could have foreseen the coronavirus pandemic when the CRC was established, and yet the research conducted at that time created a pool of knowledge which - years later and in a quite different area - is enabling significant progress to be made in combating this global challenge."
"This principle of curiosity-driven research, to which the DFG is especially committed, has been promoted in Germany for over 100 years and is once again proving to be a success story," continued Becker and referred to the founding of the DFG's predecessor organization "Notgemeinschaft der Deutschen Wissenschaft" in 1920, which the DFG is celebrating this year via its "DFG2020 - Because of Research Matters" campaign.
The DFG is the largest research funding organization in Germany and is currently funding more than 31,000 research projects in all subject areas. An annual budget of approximately 3.3 billion is available from the federal government and states and is allocated according to research quality criteria.
The spectrum of funding opportunities extends from an individual grant to major research networks. The latter is intended to enable the currently more than 270 Collaborative Research Centres to conduct research on long-term projects and to enhance the formation of core research areas and structures at universities.
The DFG also has a series of funding projects and other activities that are currently contributing directly to research relating to the coronavirus pandemic.
Even before the outbreak, there were around 20 research projects dealing with coronaviruses and the infectiousness and genetic diversity of viruses, including in several CRCs, a Clinical Research Unit, and a Priority Programme led by virologist Professor Dr Christian Drosten.
Only a few weeks after the outbreak of COVID-19, the DFG launched a large-scale call for multidisciplinary research into epidemics and pandemics.
This is intended to fund a wide range of research projects that extend from fundamental biological and medical aspects and preventive and therapeutic measures to psychological, social, cultural, legal, and ethical implications and the economy, logistics, and communication.
This call resulted in the DFG receiving almost 300 funding proposals and the first projects should be funded from the beginning of 2021.
In June, the DFG also established an interdisciplinary Commission for Pandemic Research that has 18 members from all research disciplines. Its role is to further enhance basic research in this field, support the pandemic call and the projects it funds, and to identify further areas of research.
Regarding this latter point, the DFG publishes specific calls that will enable so-called Focus Funding for a maximum of a year to fund projects dealing with questions that are particularly urgent or need to be answered at short notice.
Continue reading here:
- Individualized brain cell grafts reverse Parkinson's symptoms in monkeys - University of Wisconsin-Madison - March 3rd, 2021
- New Controversy for Stem Cell Therapy That Repairs Spinal Cords - The Great Courses Daily News - March 3rd, 2021
- Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to Clinic - BioSpace - March 3rd, 2021
- NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T - PharmiWeb.com - March 3rd, 2021
- A region within GLI1 gene could potentially be targeted as cancer treatment - News-Medical.Net - March 3rd, 2021
- Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights - Galveston County Daily News - March 3rd, 2021
- Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU... - March 3rd, 2021
- Global Autologous stem cell and Non-stem cell based Therapies Market- Industry Analysis, Growth, Segmentation and Forecast-2019-2027 - The Bisouv... - March 3rd, 2021
- Stem Cell manufacturing Market Witness an Outstanding Growth and Strong Revenue and Forecast 2027 KSU | The Sentinel Newspaper - KSU | The Sentinel... - March 3rd, 2021
- New study launches into COVID-19 vaccine responses in patients with impaired immune systems - University of Birmingham - March 3rd, 2021
- U. Cancer Center pilot projects: investigating cancer connections - The Brown Daily Herald - March 3rd, 2021
- Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network - The... - March 1st, 2021
- Human Lung and Brain Organoids Respond Differently to SARS-CoV-2 Infection in Lab Tests - UC San Diego Health - March 1st, 2021
- Contemporary Critical Care Complications of Stem Cell Transplant/Cellular Therapies - TMC News - Texas Medical Center News - March 1st, 2021
- Global Human Embryonic Stem Cells Market Size-Share Analysis and System Production | Addressing the Potential Impact of COVID-19 Top Companies FLA... - February 21st, 2021
- Studies Show ApoE4 Carriers Appear More Susceptible to COVID-19Experts Say the Jury Is Still Out - Being Patient - February 21st, 2021
- Global Stem Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 KSU | The Sentinel... - February 19th, 2021
- Associating Baseline PROs and Complications of Stem Cell Transplant - MedPage Today - February 19th, 2021
- USC scientist Ya-Wen Chen receives American Lung Association grant to advance stem cell-based lung therapies - USC News - February 10th, 2021
- Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of... - February 10th, 2021
- Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning... - February 10th, 2021
- Creative Bioarray Offers Stem Cell Lines Generation Service for Promoting Scientific Research - Press Release - Digital Journal - February 10th, 2021
- Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi... - February 10th, 2021
- The International Parkinson and Movement Disorder Society (MDS) Continues to Caution Against Unproven Cell-Based Therapies for Parkinson's Disease -... - February 10th, 2021
- Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,... - February 10th, 2021
- Money on the Move: January 27 February 2 - BioSpace - February 3rd, 2021
- Stem Cell Study Illuminates the Cause of a Devastating Inherited Heart Disorder - Newswise - February 2nd, 2021
- Experts Predict the Hottest Life Science Tech in 2021 and Beyond - The Scientist - February 2nd, 2021
- Global Apoptosis Assays Market Report 2020: Apoptosis Assay Kits Lead the Demand with 42.5% Share - Forecast to 2026 - GlobeNewswire - February 2nd, 2021
- Choroideremia Research Foundation Supports New Research to Expand Knowledge of This Rare Inherited Retinal Disease - PRNewswire - February 2nd, 2021
- APOE Tied to Increased Susceptibility to SARS-CoV-2 | ALZFORUM - Alzforum - February 2nd, 2021
- Stem Cell Research & Therapy | Home page - January 28th, 2021
- Stem cell - Wikipedia - January 28th, 2021
- stem cell | Definition, Types, Uses, Research, & Facts ... - January 28th, 2021
- Researchers use patients' cells to test gene therapy for rare eye disease - National Institutes of Health - January 28th, 2021
- Cooperation, appropriation, and vaccines relying on fetal ... - January 28th, 2021
- Stem Cell Manufacturing includes Attractiveness and Raw Material Analysis and Competitor Position Grid Analysis to 2027 | Merck KGaA, Thermo Fisher... - January 28th, 2021
- Cell Expansion Supporting Equipment Market Research Report 2020 key Insights Based on Product Type, End-use and Regional Demand Till 2027 | Beckman... - January 28th, 2021
- Global Cord Blood Stem Cells Market : Industry Analysis and Forecast (2019-2026) by Type, Application, and Region NeighborWebSJ - NeighborWebSJ - January 26th, 2021
- Animal Stem Cell Therapy Market to witness high growth in near future - Fractovia News - January 26th, 2021
- Groundbreaking Treatment for Severe COVID-19 Using Stem Cells It's Like Smart Bomb Technology in the Lung - SciTechDaily - January 6th, 2021
- Development Of New Stem Cell Type May Lead To Advances In Regenerative Medicine - Anti Aging News - January 6th, 2021
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020-2025 Business Insights and Sustainable Growth in Respective Industry - LionLowdown - January 6th, 2021
- Cell Therapy Speed and Efficiency Driven by Draper's New Way of Thinking - BioSpace - January 6th, 2021
- Chronic Kidney Disease (CKD) Drugs Market: Increasing Burden of Kidney Disease is Expected to Drive the Market - BioSpace - January 6th, 2021
- Global Circulating Tumor Cells and Cancer Stem Cells Market To Reach A New Threshold of Growth By 2026 - The Courier - January 6th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 6th, 2021
- Stem Cell Therapy Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2025 - Farming Sector - January 4th, 2021
- How brain inflammation and healing is pointing to new glioblastoma targets - FierceBiotech - January 4th, 2021
- Discover the Global Stem Cell Banking Market Opportunities, Key Manufacturers and Outlook - The Courier - December 30th, 2020
- Impacts of COVID 19 on Stem Cell Therapy Market 2020 Size, Demand, Opportunities & Forecast To 2026 - Factory Gate - December 30th, 2020
- Nociceptive neurons shown to boost hematopoiesis | 2020-12-28 - BioWorld Online - December 28th, 2020
- Global Stem Cell Therapy Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 - The Courier - December 28th, 2020
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Stem Cell Therapy Market (COVID-19 Analysis) 2020-2025 Is Booming Worldwide with Comprehensive Study Explores Huge Revenue Scope in Future - Farming... - December 28th, 2020
- Stem Cell Therapy Market Size 2020 | Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2025 - LionLowdown - December 28th, 2020
- Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Yahoo... - December 27th, 2020
- Global Adipose Stem Cells (ASCS) Market 2020 Global Insights and Technology Advancement, Trends, Opportunities and Forecast to 2027 - Factory Gate - December 27th, 2020
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire - December 17th, 2020
- Global NK Cell Therapy and Stem Cell Therapy Market: Development, Current Analysis and Estimated Forecast to 2025 - The Courier - December 17th, 2020
- I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire - December 17th, 2020
- Stem Cell Exosomes Market: Increasing advanced applications of exosomes is expected to drive the market - BioSpace - December 17th, 2020
- Creative Medical Technology Stock Price Increased 80.77%: Why It Happened - Pulse 2.0 - December 17th, 2020
- 1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive - NPR - December 17th, 2020
- California's Proposition 14: short in the arm for stem cell research - BioNews - December 15th, 2020
- Networks of genes involved in congenital heart disease revealed - News-Medical.net - December 15th, 2020
- Researchers Discover Clue to How to Protect Neurons and Encourage Their Growth - UC San Diego Health - December 15th, 2020
- Global Cancer Stem Cells Market to Boost with CAGR of 11.8% and Cross a Margin of $1,898.3 Million During the Covid-19 Outbreak Exclusive Report [150... - December 10th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - BioSpace - December 10th, 2020
- Procyon Technologies LLC and Novo Nordisk A/S to Collaborate on the Development of a Stem-Cell Based Therapy for Type 1 Diabetes - PRNewswire - December 10th, 2020
- Better education needed to give patients improved understanding of gene therapies, new review highlights - University of Birmingham - December 10th, 2020
- Extended Virus Shedding After COVID in Some Patients With Cancer - Medscape - December 10th, 2020
- Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID... - December 10th, 2020
- How do you donate stem cells? Donating cells can help treat cancer, blindness and other conditions - heres how - The Scotsman - December 6th, 2020
- Free radicals may be important for the brain to remain adaptable - News-Medical.Net - December 6th, 2020
- New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies - Newswise - December 6th, 2020
- Worldwide Stem Cell Therapy Market Insights to 2025 - Analysis and Forecasts - GlobeNewswire - December 6th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - UCLA Newsroom - December 6th, 2020
- UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies - UCLA Newsroom - December 6th, 2020
- Anatomy of a vaccine: What it takes to create a safe, effective COVID shot - University of California - December 6th, 2020